This blog post is a guest post from Edword Simpson, technical engineer at Science Exchange lab, RS Calibration.
Ensuring that everything in your laboratory is ready for any upcoming audit is a nail-biting task. The annual FDA audit for compliance with regulatory guidelines, like the current goods manufacturing process (cGMP) is especially tedious. Manufacturing processes and equipment for pharmaceuticals are regulated very carefully by the FDA and require strict adherence to industry standards.
Here are five things that aren’t always given the attention they require and could easily result in regulatory action for failing to comply with cGMP: Read the rest of this entry »
I recently talked to Matt Owens, Executive Director of Harlem Biospace. For anyone interested in biotech, startups, or the up and coming New York biotech scene, his interview below is a must-read. Check it out!
Q: Why was Harlem Biospace created?
Matt: There was so much incredible research taking place at the institutions in New York City, but there was no support system for developing that research into a company. One important first step to building those companies and commercializing that research is affordable lab space. So we built an affordable lab and working space for early-stage life science companies.
Q: What is the goal of Harlem Biospace?
Matt: The goal is to lower the barrier for commercializing a hypothesis into a technology.
Q: What kind of companies are you looking for? What’s the ideal stage and mission of the companies that apply?
Matt: The stages are very early, 1-4 people. That still covers a wide spectrum of readiness to ship a product, because the ideas are very different. It ranges from molecules for drug discovery to people with research tools that are ready to prototype and find early customers.
Most are just funding these projects themselves or have family investors, while a few have investors.
Q: What are the companies in your first batch working on?
Matt: It’s an incredibly diverse group ranging from allergy testing techniques to drug discovery to devices for preserving mouse neurons. The individuals behind them all have strong research backgrounds and a well-articulated plan for developing a company around their idea. Read the rest of this entry »
Here at Science Exchange, we aim to enable efficient scientific collaboration. One of the biggest hurdles researchers face on our site is deciding where to send their requests. Conversely, it can be frustrating for lab admins to receive requests outside their capabilities. With that in mind, we are working on improving our search experience. This update will be available at the end of next month.
In preparation for our improved search experience, we’ve launched a tagging feature for labs. Labs can apply tags, such as equipment names, to their services, which will allow researchers to narrow their search to only labs that have the machine they need. Also, labs that have signed agreements with Science Exchange, like our Non-Disclosure Agreement, will receive storefront tags, allowing researchers who require that level of protection to quickly identify appropriate labs.
If you’re a lab admin on Science Exchange, we encourage you to begin tagging your services and storefront now! This will ensure that researchers will be able to find your lab more easily with our new search experience.
February 20, 2015 | Posted by Tess Mayall in Company |
Science Exchange CEO Elizabeth Iorns was on This Week in Startups for an hour-long deep dive into the state of science. Listen and learn about everything from cancer biology to AI to scientific publishing!
February 9, 2015 | Posted by Reproducibility Project Core Team in Reproducibility |
“Reproducibility is actually the heart of science. The fact that not everything is reproducible is not a surprise.” – Eric Lander, head of the Broad Institute at MIT in a recent Washington Post article.
“We’re always in a gray area between perfect truth and complete falsehood,” The best researchers can do is edge closer to truth. – Giovanni Parmigiani, Dana-Farber Cancer Institute in a recent ScienceNews article
The Reproducibility Project, a collaboration between Science Exchange and the Center for Open Science, is independently replicating some of the most impactful studies in cancer biology. Along the way, not only will the collaboration shepherd 50 studies through the process of replication and meta-analysis, but it will also help to mature the discussion around reproducibility more generally. Where do the biggest challenges lie? What are some of the key predictors of whether experiments are reproducible? The answer to these questions will be critical as the reproducibility initiative gains traction.
Since December, experimental work has begun on four more replication studies, and three more Registered Reports have been published in eLife (with a fourth* accepted and on the way):
In addition, Sean Morrison, director of the Children’s Medical Institute at the University of Texas–Southwestern and a senior editor at eLife, has written an editorial introducing the Reproducibility Project: Cancer Biology, highlighting the role this project could play in beginning to reform scientific discovery methods to maximize reproducibility. He notes that:
“to be responsible stewards of the public’s investment in this work we have to maximize the pace of discovery and the efficiency with which discoveries get translated to the benefit of patients. By gauging the fraction of high-impact results that are not reproducible, we can consider what further steps should be taken to promote good science….[M]easuring the magnitude of the problem with efforts like the Reproducibility Project: Cancer Biology is an important step in the right direction” (2).
Recently I spoke with Ries Robinson from our lab Medici Technologies. Everything about Medici Technologies is captivating, from the story behind their unique name to their interesting approach to data analysis. Check out more on their specialized approach below!
Q: What is Medici Technologies’ specialty?
Ries: We analyze data for groups or companies that have data that is so complex that it exceeds their resources. We are a consulting firm that provides expertise in data analysis.
Q: Why did you choose Medici as your name?
Ries: The Medici Effect is the idea that significant breakthroughs in innovation and technology often occur when you cross-pollinate fields. It stems from the Renaissance. For example, a Renaissance family would make the plumber work with the weaver, or someone with a different skill set, and that’s part of what initiated the Renaissance movement.
A lot of what we do is pull different ideas or algorithms from different places. Historically, we’ve worked on complex data analysis of optical signals for measuring chemicals or analytes in the body, but some of our greatest breakthroughs have been by taking algorithms from non-traditional sectors. For example, we can utilize song recognition and gesture recognition tools to classify tissue types. Utilizing methods developed in other applications has been extremely beneficial. Read the rest of this entry »
November 17, 2014 | Posted by Becca Swett in New Feature |
Today, we’re excited to introduce a new, centralized order management experience on Science Exchange, focused on improving collaboration and messaging.
We take feedback from our researchers and labs very seriously and have designed the new order management experience with your input in mind. The new design, which went live earlier today, moves messaging front and center and introduces a timeline of all events.
A collaborative workspace
The new workspace allows researchers and lab members to intuitively collaborate on orders. Any member of the lab can see all messages on an order, enabling multiple members of the same lab to coordinate easily and efficiently under this team view. Everyone who has access to this order is shown on the righthand side.
Communication is key
Since open communication between researcher and lab is of utmost importance, the new order page focuses heavily on messaging. Messages and files can be sent during any stage of an order, from the top of any page. Users can start sending messages as soon as a request is posted, and continue sending them even after an order is complete. As always, there is no limit on the size or quantity of uploaded files. All messages and files appear in the main Timeline tab, along with all other events.
Keep track of your order
It can be difficult to keep track of research projects, so we’ve made it easy for you. The main timeline shows everything that has happened in reverse chronological order. You can always reference the order status indicator in the upper right hand corner. All available actions, like shipping samples or accepting a quote, are shown below the indicator for easy access.
Easy access to the latest details
Because research projects are updated regularly, we’ve added the Order Details tab. Here, you can always see the latest version of the order, no matter what state it is in. You can also download quote summaries and billing documents from the Files tab.
We think you will find that the rest of your overall workflow is largely the same, just more beautiful and intuitive. As of this morning, all orders will reflect the changes. If you have any questions, please don’t hesitate to reach out to us at email@example.com or share feedback.
About the author
Becca joined as Science Exchange’s first Product Manager, excited to help bring efficiency to scientific research. She previously launched SurveyMonkey Enterprise and WePay Canada. She has a degree from Stanford in Mathematical & Computational Science and enjoys cooking and home improvement in her spare time.
We are proud to announce today that we have partnered with the Prostate Cancer Foundation (PCF), with funding from the Movember Foundation, to reproduce findings that have implications for prostate cancer patients. We will be collaborating with PCF to identify faster, high-impact biomedical findings that that can improve early detection and new cures.
PCF’s Chief Science Officer, Dr. Soule stated “This first-in-field foundation initiative is all about getting the smart stuff to patients quicker. We will see an acceleration of progress due to the mobilization of resources against the robust findings.”
Our Software Engineer Michael Kompanets with last year’s Movember mustache.
Science Exchange has a been long-time fan and supporter of PCF and the Movember Foundation (see picture to the right), so we are thrilled to be working with them to incorporate replication studies into their funding strategy. We will be utilizing the best practices that we’ve established for our Reproducibility Project: Cancer Biology to enable confirmation of high potential exploratory research results. Our hope is that by identifying robust reproducible results, we can accelerate prostate cancer research.
“The Movember Foundation is committed to accelerating the translation of promising discoveries into new tests and treatments,” said Paul Villanti, Executive Director of Programs, Movember Foundation. “Through quicker validation of the science, and if the science is true, we can help find new cures and prevent prostate cancer in more men at a faster rate. The Movember Foundation is confident that this initiative will play an important role in supporting this goal.” Read the rest of this entry »
October 14, 2014 | Posted by Reproducibility Project Core Team in Reproducibility |
There has been growing concern in the scientific community over the last several years about a lack of reproducible results in the biomedical research community. Recently, two large pharmaceutical companies (Amgen and Bayer) announced that they could only reproduce a small fraction of published preclinical cancer biology studies. These results have shocked the scientific community, and have lead to calls mandating an overhaul of both funding and publishing practices to address the crisis. The NIH, as well as the journals Nature and Science, are all proposing strategies to help improve the research process.
However, a major question remains: Why weren’t these experiments reproducible? Valid arguments exist suggesting scientists are falling prey to poor experimental design, flawed statistical analysis, and/or biased data interpretation, all of which can prevent their results from being replicable. However, there are many innocuous reasons why a particular experiment might fail to replicate the original results, from errors or changes in the protocol, to a lack of expertise in performing a particular technique, to unknown factors that produce variability in results. Unfortunately, it’s hard to draw conclusions from the Amgen and Bayer studies because these companies made none of their data or methods public.
The birth of the Reproducibility Project: Cancer Biology
We believe that in order to really understand the crisis in reproducibility, including its prevalence, scope and underlying causes, we need a large dataset of actual replication experiments. These replications must be conducted in a rigorously empirical fashion, using detailed protocols as close to the original study as possible, and conducted by expert scientists trained in the original techniques. Most importantly, the details of these replication datasets must be freely available to everyone.